These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8720536)

  • 1. Islet cell antibodies at diagnosis, but not leanness, relate to a better cardiovascular risk factor profile 5 years after diagnosis of NIDDM.
    Gottsäter A; Ahmed M; Lilja B; Fernlund P; Sundkvist G
    Diabetes Care; 1996 Jan; 19(1):60-3. PubMed ID: 8720536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis.
    Niskanen LK; Tuomi T; Karjalainen J; Groop LC; Uusitupa MI
    Diabetes Care; 1995 Dec; 18(12):1557-65. PubMed ID: 8722051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between insulin resistance and risk factors for cardiovascular disease in Japanese non-insulin-dependent diabetic patients.
    Wasada T; Kuroki H; Arii H; Maruyama A; Aoki K; Katsumori K; Saito S; Hanada H; Omori Y
    Diabetes Res Clin Pract; 1994 Oct; 25(3):191-8. PubMed ID: 7851274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy.
    Chen J; Gall MA; Yokoyama H; Jensen JS; Deckert M; Parving HH
    Diabetes Care; 1996 Feb; 19(2):130-4. PubMed ID: 8718432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinsulin secretion during the first 3 years after diagnosis in diabetic patients with and without islet cell antibodies.
    Gottsäter A; Owens DR; Luzio S; Sundkvist G
    Diabetes Care; 1996 Jun; 19(6):659-62. PubMed ID: 8725869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral atherosclerosis and serum lipoprotein(a) in diabetes.
    Wollesen F; Dahlén G; Berglund L; Berne C
    Diabetes Care; 1999 Jan; 22(1):93-8. PubMed ID: 10333909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.
    Kobayashi T; Nakanishi K; Murase T; Kosaka K
    Diabetes; 1996 May; 45(5):622-6. PubMed ID: 8621013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM.
    Vergès BL; Lagrost L; Vaillant G; Petit JM; Cohen M; Gambert P; Brun JM
    Diabetes; 1997 Jan; 46(1):125-32. PubMed ID: 8971092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
    Nagi DK; Yudkin JS
    Diabetes Care; 1993 Apr; 16(4):621-9. PubMed ID: 8462390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM.
    Savage S; Estacio RO; Jeffers B; Schrier RW
    Diabetes Care; 1996 Nov; 19(11):1243-8. PubMed ID: 8908388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factor analyses for macrovascular complication in nonobese NIDDM patients. Multiclinical Study for Diabetic Macroangiopathy (MSDM).
    Ito H; Harano Y; Suzuki M; Hattori Y; Takeuchi M; Inada H; Inoue J; Kawamori R; Murase T; Ouchi Y; Umeda F; Nawata H; Orimo H
    Diabetes; 1996 Jul; 45 Suppl 3():S19-23. PubMed ID: 8674883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM. A randomized controlled study.
    Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
    Diabetes Care; 1997 Jun; 20(6):913-21. PubMed ID: 9167099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profile of lean NIDDM in South India.
    Mohan V; Vijayaprabha R; Rema M; Premalatha G; Poongothai S; Deepa R; Bhatia E; Mackay IR; Zimmet P
    Diabetes Res Clin Pract; 1997 Nov; 38(2):101-8. PubMed ID: 9483373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.
    Lehto S; Rönnemaa T; Haffner SM; Pyörälä K; Kallio V; Laakso M
    Diabetes; 1997 Aug; 46(8):1354-9. PubMed ID: 9231662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography.
    Vanzetto G; Halimi S; Hammoud T; Fagret D; Benhamou PY; Cordonnier D; Denis B; Machecourt J
    Diabetes Care; 1999 Jan; 22(1):19-26. PubMed ID: 10333898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid profile and its relation to fasting insulin level in non-insulin dependent diabetes mellitus (NIDDM).
    Uddin F; Miah AK
    Bangladesh Med Res Counc Bull; 1995 Aug; 21(2):64-72. PubMed ID: 8815864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects.
    Nakano S; Fukuda M; Hotta F; Ito T; Ishii T; Kitazawa M; Nishizawa M; Kigoshi T; Uchida K
    Diabetes; 1998 Sep; 47(9):1501-6. PubMed ID: 9726241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.
    Heald AH; Siddals KW; Fraser W; Taylor W; Kaushal K; Morris J; Young RJ; White A; Gibson JM
    Diabetes; 2002 Aug; 51(8):2629-36. PubMed ID: 12145180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM.
    Niskanen LK; Penttilã I; Parviainen M; Uusitupa MI
    Diabetes Care; 1996 May; 19(5):486-93. PubMed ID: 8732714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-cell function in relation to islet cell antibodies during the first 3 yr after clinical diagnosis of diabetes in type II diabetic patients.
    Gottsäter A; Landin-Olsson M; Fernlund P; Lernmark A; Sundkvist G
    Diabetes Care; 1993 Jun; 16(6):902-10. PubMed ID: 8325204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.